Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Etminani Esfahani, Maryam ^a   Khalili, Hossein ^b   Jafari, Sirous ^c   Abdollahi, Alireza ^c   Dashti Khavidaki, Simin ^b  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Efavirenz; HIV; Vitamin D

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; BIOLOGICAL MARKER; COLLAGEN TELOPEPTIDASE; EFAVIRENZ; METALLOPROTEINASE; OSTEOCALCIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VITAMIN; VITAMIN D;

ADULT; ARTICLE; BLOOD; BONE; BONE REMODELING; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRAN; MALE; METABOLISM; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDY; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; DIETARY SUPPLEMENTS; FEMALE; HIV INFECTIONS; HUMANS; IRAN; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; OSTEOCALCIN; PREVALENCE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84862185613     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-204     Document Type: Article

References (28)

1. The Joint United Nations Programme on AIDS (UN-AIDS), AIDS Epidemic Update Geneva: World Health Organization 2009
2. The Rapidly Evolving Research on Vitamin D Among HIV-Infected Populations. ET Overton, MT Yin, Curr Infect Dis Rep 2011 13 83 93 10.1007/s11908-010-0144-x 21308459
3. The role of HIV and antiretroviral therapy in bone disease. F Gutiérrez, M Masiá AIDS Rev 2011 13 109 118 21587342
4. HIV and bone metabolism. I Ofotokun, MN Weitzmann, Discov Med 2011 11 385 393 21616037
5. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. G Madeddu, A Spanu, P Solinas, GM Calia, C Lovigu, F Chessa, M Mannazzu, A Falchi, MS Mura, G Madeddu, Q J Nucl Med Mol Imaging 2004 48 39 48 15195003 (Pubitemid 39069663)
6. Bone, fracture and frailty. J Hoy, Curr Opin HIV AIDS 2011 6 309 314 10.1097/COH.0b013e3283478741 21537171
7. Biochemical markers of bone turnover: part I: biochemistry and variability. MJ Seibel, Clin Biochem Rev 2005 26 97 122 16648882
8. Bone remodeling. DJ Hadjidakis, II Androulakis, Ann N Y Acad Sci 2006 1092 385 396 10.1196/annals.1365.035 17308163 (Pubitemid 47092355)
9. HIV and bone disease. B Stone, D Dockrell, C Bowman, E McCloskey, Arch Biochem Biophys 2010 503 66 77 10.1016/j.abb.2010.07.029 20682280
10. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. T Welz, K Childs, F Ibrahim, M Poulton, CB Taylor, CF Moniz, FA Post, AIDS 2010 31 1923 1928
11. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. CN Dao, P Patel, ET Overton, F Rhame, SL Pals, C Johnson, T Bush, JT Brooks, Clin Infect Dis 2011 52 396 405 10.1093/cid/ciq158 21217186
12. Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use? A Pasquet, N Viget, F Ajana, X de la Tribonniere, S Dubus, J Paccou, I Legroux-Gérot, H Melliez, B Cortet, Y Yazdanpanah, AIDS 2011 25 873 874 10.1097/QAD. 0b013e32834542fa 21412064
13. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. J Huang, L Meixner, S Fernandez, JA McCutchan, AIDS 2009 23 51 57 10.1097/QAD.0b013e32831c8adc 19050386
14. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. E Seminari, A Castagna, A Soldarini, L Galli, G Fusetti, F Dorigatti, H Hasson, A Danise, M Guffanti, A Lazzarin, A Rubinacci, HIV Med 2005 6 145 150 10.1111/j.1468-1293.2005.00278.x 15876279 (Pubitemid 40740329)
15. Bone turnover markers in HIV disease. H Haskelberg, A Carr, S Emery, AIDS Rev 2011 13 240 250 21975360
16. Biochemical markers of bone turnover: part II: Clinical Applications in the Management of Osteoporosis. MJ Seibel, Clin Biochem Rev 2006 27 123 138 17268581
17. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. R Vieth, Am J Clin Nutr 1999 69 842 856 10232622 (Pubitemid 29205056)
18. The effect of a single dose versus a daily dose of cholecalciferol on the serum 25-hydroxycholecalciferol and parathyroid hormone levels in the elderly with secondary hyperparathyroidism living in a low-income housing unit. MO Premaor, R Scalco, MJ da Silva, PE Froehlich, TW Furlanetto, J Bone Miner Metab 2008 26 603 608 10.1007/s00774-008-0858-0 18979160
19. A single dose of vitamin D enhances immunity to mycobacteria. AR Martineau, RJ Wilkinson, KA Wilkinson, SM Newton, B Kampmann, BM Hall, GE Packe, RN Davidson, SM Eldridge, ZJ Maunsell, SJ Rainbow, JL Berry, CJ Griffiths, Am J Respir Crit Care Med 2007 176 208 213 10.1164/rccm.200701-007OC 17463418 (Pubitemid 47057859)
20. The effect of oral and parenteral vitamin D supplementation in the elderly: a prospective, double-blinded, randomized, placebo-controlled study. H Sakalli, D Arslan, AE Yucel, Rheumatol Int 2011 2 1 2 May 10. [Epub ahead of print]
21. Functions of RANKL/RANK/OPG in bone modeling and remodeling. BF Boyce, L Xing, Arch Biochem Biophys 2008 473 139 146 10.1016/j.abb.2008.03.018 18395508
22. The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. D Vega, NM Maalouf, K Sakhaee, J Clin Endocrinol Metab 2007 92 4514 4521 10.1210/jc.2007-0646 17895323 (Pubitemid 350223419)
23. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. H Takasu, A Sugita, Y Uchiyama, N Katagiri, M Okazaki, E Ogata, K Ikeda, J Clin Invest 2006 116 528 535 10.1172/JCI24742 16424941 (Pubitemid 43228371)
24. Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. PA Baldock, GP Thomas, JM Hodge, SU Baker, U Dressel, PD O'Loughlin, GC Nicholson, KH Briffa, JA Eisman, EM Gardiner, J Bone Miner Res 2006 211 618 626
25. No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year. R Jorde, M Sneve, PA Torjesen, Y Figenschau, JB Hansen, G Grimnes, Nutr J 2010 7 1
26. Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based Perspective. A Barkhordarian, R Ajaj, MH Ramchandani, G Demerjian, R Cayabyab, S Danaie, N Ghodousi, N Iyer, N Mahanian, L Phi, A Giroux, E Manfrini, N Neagos, M Siddiqui, OS Cajulis, XM Brant, P Shapshak, F Chiappelli, Patholog Res Int 2011 2011 359242 Epub 2011 May 21 21660263
27. Daily and cyclic parathyroid hormone in women receiving alendronate. F Cosman, J Nieves, M Zion, L Woelfert, M Luckey, R Lindsay, N Engl J Med 2005 353 566 575 10.1056/NEJMoa050157 16093465 (Pubitemid 41138938)
28. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. P Chen, JH Satterwhite, AA Licata, EM Lewiecki, AA Sipos, DM Misurski, RB Wagman, J Bone Miner Res 2005 20 962 970 10.1359/JBMR.050105 15883636 (Pubitemid 40712820)